Nuclea Biotechnologies

About Nuclea Biotechnologies

Founded in 2005, Nuclea Biotechnologies focuses on the development and provision of diagnostic assays and kits for the early detection and monitoring of biomarkers, primarily in the fields of oncology and endocrinology. The company operates a CLIA-certified laboratory in Cambridge, Massachusetts, where it offers a suite of validated and reimbursable mass spectrometry tests for proteins linked to cancer and various chronic diseases. Its business model encompasses the sale of In Vitro Diagnostic (IVD) and Research Use Only (RUO) diagnostic kits, alongside providing clinical laboratory testing services. A significant milestone for the company was the 2013 acquisition of Oncogene Sciences' ELISA products, which included the HER-2/neu IVD diagnostic kit for metastatic breast cancer. This strategic acquisition broadened its product portfolio and strengthened its market position in cancer diagnostics.

Nuclea Biotechnologies serves a client base that includes clinical laboratories, research institutions, and pharmaceutical companies. The company's core technological strength lies in its proprietary discovery platforms and its focus on proteomics, which involves analyzing the proteins in an individual's system to get a real-time assessment of disease states. This approach allows for more personalized diagnostic information. The Cambridge facility is equipped for advanced mass spectrometry assays that analyze serum or plasma proteins associated with conditions like diabetes and metabolic syndrome, in addition to its oncology offerings.

The company was founded by Patrick Muraca, who has a background in the life sciences and business development. He has held positions at companies like Millipore Corporation and has been involved with various biotechnology and healthcare ventures, bringing industry experience to the company's leadership. Nuclea generates revenue through the direct sale of its diagnostic kits and from the services provided by its clinical testing laboratory, positioning itself at the intersection of diagnostics development and clinical service provision in the life sciences sector. The company also states that its proprietary discovery platforms have led to a collection of novel biomarkers and antibodies that continue to fill its assay pipeline, indicating an ongoing commitment to research and development.